

A. Bustamante has received reimbursement for attending a symposium from Astra Zeneca, Grifols, Almirall and Boehinger-Ingelheim. Fees for speaking from Astra-Zeneca, Almirall, MSD, Boehinger-Ingelheim, Pfizer.

I. Ferrarotti received research grants from Talecris/Grifols, provided paid lectures for Kedrion Italy, and received support for attending ERS conferences from Talecris/Grifols.

B. Lara received honoraria for developing REDAAT database management from Grifols.

M. Luisetti received research grants from Talecris/Grifols, provided paid lectures for Kedrion Italy, and received financial support to the AATD detection programme from Talecris/Grifols and Kedrion Italy.

M. Miravittles has received speaker fees from Boehringer Ingelheim, Pfizer, AstraZeneca, Bayer Schering, Novartis, Talecris, Nycomed, Merck, Sharp & Dohme and Novartis, and consulting fees from Boehringer Ingelheim, Pfizer, GSK, AstraZeneca, Bayer Schering, Novartis, Almirall, Merck, Sharp & Dohme and Nycomed.

S. Ottaviani received research grants from Talecris/Grifols and received support for attending ERS conferences from Talecris/Grifols.